NG101 is an oral, small molecule peripherally acting dopamine D2 receptor antagonist currently in Phase 2 clinical development for the treatment of gastroparesis.
- Gastroparesis is a chronic, severe and debilitating disorder that may be associated with dysfunction in the enteric nervous system, causing the movement of food from the stomach to the small intestine to slow or stop, and preventing or disrupting normal digestion. Patients with gastroparesis often limit their intake of food and liquids, leading to poor nutrition and dehydration, which in turn can ultimately require hospitalization.
D2 receptor antagonists are an established class of therapeutics with demonstrated efficacy in relieving gastroparesis symptoms; however, their use has been limited because they are associated with an increased risk of serious CNS and cardiac side effects.
- NG101 is a proprietary mesylate salt form of metopimazine, a D2 receptor antagonist that has not been associated with an increased risk of serious CNS or cardiac side effects. Metopimazine has been approved and prescribed in France for over 40 years for the symptomatic treatment of nausea and vomiting and has been shown to be safe and generally well-tolerated for those indications. Metopimazine has never been evaluated for the treatment of gastroparesis.
We are conducting a 12-week, randomized, double-blind, placebo-controlled Phase 2 clinical trial of NG101, in which we are enrolling patients with moderate to severe idiopathic or diabetic gastroparesis.
We hold the worldwide rights to NG101.